<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes</journal-id><journal-id journal-id-type="publisher-id">diabetes</journal-id><journal-title>Diabetes</journal-title><issn pub-type="ppub">0012-1797</issn><issn pub-type="epub">1939-327X</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">5782066</article-id><article-id pub-id-type="doi">10.2337/db07-0763</article-id><article-id pub-id-type="pmid">18443205</article-id><article-categories><subj-group subj-group-type="heading"><subject>Signal Transduction</subject></subj-group></article-categories><title-group><article-title>siRNA-Mediated Reduction of Inhibitor of Nuclear Factor-&#x003ba;B Kinase Prevents Tumor Necrosis Factor-&#x003b1;&#x02013;Induced Insulin Resistance in Human Skeletal Muscle</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Austin</surname><given-names>Reginald L.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rune</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bouzakri</surname><given-names>Karim</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zierath</surname><given-names>Juleen R.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Krook</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden</aff><aff id="aff2"><label>2</label>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden</aff><author-notes><fn><p>Corresponding author: Anna Krook, <email>anna.krook&#x00040;ki.se</email></p></fn></author-notes><pub-date pub-type="ppub"><month>8</month><year>2008</year></pub-date><volume>57</volume><issue>8</issue><fpage>2066</fpage><lpage>2073</lpage><history><date date-type="received"><day>5</day><month>6</month><year>2007</year></date><date date-type="accepted"><day>18</day><month>4</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008, American Diabetes Association</copyright-statement><license license-type="open-access"><p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</p></license></permissions><self-uri xlink:title="pdf" xlink:href="zdb00808002066.pdf"/><abstract><p><bold>OBJECTIVE&#x02014;</bold>Proinflammatory cytokines contribute to systemic low-grade inflammation and insulin resistance. Tumor necrosis factor (TNF)-&#x003b1; impedes insulin signaling in insulin target tissues. We determined the role of inhibitor of nuclear factor-&#x003ba;B kinase (IKK)&#x003b2; in TNF-&#x003b1;&#x02013;induced impairments in insulin signaling and glucose metabolism in skeletal muscle.</p><p><bold>RESEARCH DESIGN AND METHODS&#x02014;</bold>Small interfering RNA (siRNA) was used to silence IKK&#x003b2; gene expression in primary human skeletal muscle myotubes from nondiabetic subjects. siRNA gene silencing reduced IKK&#x003b2; protein expression 73&#x00025; (<italic>P</italic> &#x0003c; 0.05). Myotubes were incubated in the absence or presence of insulin and/or TNF-&#x003b1;, and effects of IKK&#x003b2; silencing on insulin signaling and glucose metabolism were determined.</p><p><bold>RESULTS&#x02014;</bold>Insulin increased glucose uptake 1.7-fold (<italic>P</italic> &#x0003c; 0.05) and glucose incorporation into glycogen 3.8-fold (<italic>P</italic> &#x0003c; 0.05) in myotubes from nondiabetic subjects. TNF-&#x003b1; exposure fully impaired insulin-mediated glucose uptake and metabolism. IKK&#x003b2; siRNA protected against TNF-&#x003b1;&#x02013;induced impairments in glucose metabolism, since insulin-induced increases in glucose uptake (1.5-fold; <italic>P</italic> &#x0003c; 0.05) and glycogen synthesis (3.5-fold; <italic>P</italic> &#x0003c; 0.05) were restored. Conversely, TNF-&#x003b1;&#x02013;induced increases in insulin receptor substrate-1 serine phosphorylation (Ser<sup>312</sup>), Jun NH<sub>2</sub>-terminal kinase phosphorylation, and extracellular signal&#x02013;related kinase-1/2 mitogen-activated protein kinase (MAPK) phosphorylation were unaltered by siRNA-mediated IKK&#x003b2; reduction. siRNA-mediated IKK&#x003b2; reduction prevented TNF-&#x003b1;&#x02013;induced insulin resistance on Akt Ser<sup>473</sup> and Thr<sup>308</sup> phosphorylation and phosphorylation of the 160-kDa Akt substrate AS160. IKK&#x003b2; silencing had no effect on cell differentiation. Finally, mRNA expression of GLUT1 or GLUT4 and protein expression of MAPK kinase kinase kinase isoform 4 (MAP4K4) was unaltered by IKK&#x003b2; siRNA.</p><p><bold>CONCLUSIONS&#x02014;</bold>IKK&#x003b2; silencing prevents TNF-&#x003b1;&#x02013;induced impairments in insulin action on Akt phosphorylation and glucose uptake and metabolism in human skeletal muscle.</p></abstract></article-meta><notes><fn-group><fn><p>Published ahead of print at <ext-link ext-link-type="uri" xlink:href="http://diabetes.diabetesjournals.org">http://diabetes.diabetesjournals.org</ext-link> on 28 April 2008.</p></fn><fn><p>The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked &#x0201c;advertisement&#x0201d; in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.</p></fn></fn-group></notes></front><body><p>Subclinical inflammation plays a role in the etiology of peripheral insulin resistance in type 2 diabetes (<xref ref-type="bibr" rid="r1">1</xref>&#x02013;<xref ref-type="bibr" rid="r6">6</xref>). Correlative studies in type 2 diabetic patients link excessive levels of the proinflammatory cytokine tumor necrosis factor (TNF)-&#x003b1; in adipose tissue (<xref ref-type="bibr" rid="r7">7</xref>), blood plasma (<xref ref-type="bibr" rid="r8">8</xref>&#x02013;<xref ref-type="bibr" rid="r10">10</xref>), and skeletal muscle (<xref ref-type="bibr" rid="r11">11</xref>) with whole-body insulin resistance (<xref ref-type="bibr" rid="r12">12</xref>,<xref ref-type="bibr" rid="r13">13</xref>). In vivo studies provide evidence that an acute infusion of TNF-&#x003b1; into healthy humans rapidly induces skeletal muscle insulin resistance by disrupting insulin signaling to GLUT4 translocation without altering the hepatic glucose production (<xref ref-type="bibr" rid="r1">1</xref>). Thus, the identification and characterization of TNF-&#x003b1;&#x02013;sensitive targets may provide insight into mechanism(s) for the development of peripheral insulin resistance in response to inflammatory stress.</p><p>TNF-&#x003b1; is principally secreted by activated macrophages in response to infection and stress. Two unique membrane receptors, TNF-&#x003b1; receptor (TNFR)1 and TNFR2, mediate the biological effects of TNF-&#x003b1; (<xref ref-type="bibr" rid="r14">14</xref>). The TNFR1 receptor subtype transduces TNF-&#x003b1; signaling to the transcription factor nuclear factor-&#x003ba;B (NF-&#x003ba;B) (<xref ref-type="bibr" rid="r14">14</xref>). TNF-&#x003b1;&#x02013;induced activation of NF-&#x003ba;B is mediated by inhibitor of nuclear factor-&#x003ba;B kinase (IKK)&#x003b2;, a serine kinase involved in the phosphorylation and subsequent degradation of inhibitor of nuclear factor-&#x003ba;B (I&#x003ba;B), which leads to the activation of the transcription factor NF-&#x003ba;B (<xref ref-type="bibr" rid="r15">15</xref>&#x02013;<xref ref-type="bibr" rid="r18">18</xref>). IKK&#x003b2; has been implicated in the development of insulin resistance (<xref ref-type="bibr" rid="r19">19</xref>). High doses of salicylates target and inhibit IKK&#x003b2; to sensitize insulin signaling and reverse the associated pathogenic characteristics including hyperglycemia, hyperinsulinemia, and dyslipidemia in diabetic mice (<xref ref-type="bibr" rid="r3">3</xref>,<xref ref-type="bibr" rid="r20">20</xref>). The proposed mechanism by which salicylates sensitize insulin signaling to glucose uptake involves inhibition of IKK&#x003b2; (<xref ref-type="bibr" rid="r3">3</xref>,<xref ref-type="bibr" rid="r20">20</xref>) and enhanced insulin signaling to metabolic end points (<xref ref-type="bibr" rid="r21">21</xref>). Collectively, these data implicate a role for IKK&#x003b2;-mediated events in the pathogenesis of insulin resistance in obesity and type 2 diabetes.</p><p>TNF-&#x003b1; directly induces insulin resistance in primary human skeletal muscle cells (<xref ref-type="bibr" rid="r22">22</xref>). TNF-&#x003b1;&#x02013;mediated insulin resistance can be rescued via small interfering RNA (siRNA)-mediated silencing of mitogen-activated protein kinase kinase kinase kinase isoform 4 (MAP4K4) (<xref ref-type="bibr" rid="r22">22</xref>), an upstream regulator of Jun NH<sub>2</sub>-terminal kinase (JNK) and extracellular signal&#x02013;related kinase (ERK)1/2 (p42/44 mitogen-activated protein kinase &#x0005b;MAPK&#x0005d;) kinase (<xref ref-type="bibr" rid="r22">22</xref>&#x02013;<xref ref-type="bibr" rid="r24">24</xref>). In addition to mediating insulin resistance through the activation of JNK, TNF-&#x003b1; exerts negative effects on insulin signaling through the serine/threonine kinase IKK&#x003b2; in cultured immortalized cells (<xref ref-type="bibr" rid="r25">25</xref>,<xref ref-type="bibr" rid="r26">26</xref>) and in animal models of type 2 diabetes (<xref ref-type="bibr" rid="r3">3</xref>). Here, we test the hypothesis that IKK&#x003b2; is an intermediate kinase for TNF-&#x003b1; action on insulin-mediated glucose uptake in primary human skeletal muscle cells. We provide evidence that TNF-&#x003b1;&#x02013;induced insulin resistance on signal transduction at the level of Akt is prevented by siRNA-mediated silencing of IKK&#x003b2;. We also show that the TNF-&#x003b1;&#x02013;induced impairments on insulin-mediated glucose uptake and glycogen synthesis in primary human myotubes are prevented by IKK&#x003b2; inhibition. Thus, strategies to inhibit IKK&#x003b2; expression in human skeletal muscle may prevent insulin resistance associated with inflammatory stress.</p><sec><title>RESEARCH DESIGN AND METHODS</title><p>Skeletal muscle biopsies were obtained with informed consent from nondiabetic individuals (seven male and two female) scheduled for abdominal surgery. The mean age and BMI of the subjects were 57 &#x000b1; 2 years and 25.8 &#x000b1; 0.9 kg/m<sup>2</sup>, respectively. None of the subjects had any known metabolic disorders, and all presented with normal fasting plasma glucose values (5.5 &#x000b1; 0.3 mmol/l). The protocols in this study were approved by the ethics committee at Karolinska Institutet.</p><p>DMEM (Dulbecco's modified Eagle's medium), DMEM F-12, fetal bovine serum, penicillin, streptomycin, and Fungizone were obtained from Invitrogen (Stockholm, Sweden). Recombinant human TNF-&#x003b1; and general laboratory reagents were obtained from Sigma (St. Louis, MO), PD98059 was obtained from Calbiochem (La Jolla, CA), and radioactive reagents were purchased from Amersham (Uppsala, Sweden).</p><sec><title>Cell culture and siRNA transfection.</title><p>Satellite cells were isolated from muscle biopsies and cultured as previously described (<xref ref-type="bibr" rid="r27">27</xref>). IKK&#x003b2;-specific siRNA oligos were purchased from Ambion (Austin, TX). Myotubes transfected with oligos against a scrambled sequence (scrambled siRNA) were used as a control. Myotubes were transfected using Lipofectamine 2000 (Invitrogen, Sweden) as previously described (<xref ref-type="bibr" rid="r28">28</xref>).</p></sec><sec><title>Western blot analysis.</title><p>Cells were harvested and protein concentration was determined using the Pierce method. After protein determination, aliquots of lysates were mixed with 4&#x000d7; Laemmli-sample buffer, and proteins were separated by SDS-PAGE. Proteins were visualized by enhanced chemiluminescence and quantified by densitometry (<xref ref-type="bibr" rid="r29">29</xref>). TNF-&#x003b1;&#x02013;induced degradation of I&#x003ba;B&#x003b1; was analyzed in lysates by immunoblot analysis with anti-I&#x003ba;B&#x003b1; (Cell Signaling, Beverly, MA). Signaling parameters were investigated using phosphospecific antibodies against Akt (Ser<sup>473</sup>), Akt (Thr<sup>308</sup>), ERK1/2, p42/44 MAPK kinase Thr<sup>202</sup>/Tyr<sup>204</sup>, stress-activated protein kinase/JNK (Thr<sup>183/185</sup>), glycogen synthase kinase (GSK)-3&#x003b2; (Ser<sup>9</sup>), and phospho-Akt Substrate (RXRXXS/T) (Cell Signaling). Antibodies against phospho&#x02013;insulin receptor substrate (IRS)-1 Ser<sup>312</sup> and total IRS-1 were purchased from Upstate (Charlottesville, VA). Antibodies against total IKK&#x003b2;, Akt, and ERK were from Cell Signaling. Mitogen-activated protein kinase kinase (MEK) isoform 4 (MAP2K4) and MAP4K4 antibodies were obtained from Abgent (San Diego, CA), glyceraldehyde-3-phosphate dehydrogenase from Santa Cruz Biotechnology (Santa Cruz, CA), and Desmin from Abcam (Cambridge, U.K.).</p></sec><sec><title>Glucose uptake and metabolism.</title><p>Differentiated primary human muscle myotubes were exposed to saline or TNF-&#x003b1; (20 ng/ml) for 2 h. Thereafter, myotubes were incubated in the absence or presence of insulin (120 nmol/l), and 2-deoxyglucose uptake or glucose incorporation into glycogen was determined, as previously described (<xref ref-type="bibr" rid="r29">29</xref>). Total protein concentration was assessed using the Bradford method (Bio-Rad, Richmond, CA). Data are reported as nmol &#x000b7; mg<sup>&#x02212;1</sup> &#x000b7; min<sup>&#x02212;1</sup>.</p></sec><sec><title>Statistics.</title><p>Data are presented as means &#x000b1; SEM. Statistical differences were determined by Student's <italic>t</italic> test or ANOVA using Fisher's least significant differences test for post hoc determination.</p></sec></sec><sec><title>RESULTS</title><sec><title>IKK&#x003b2; silencing in myotubes.</title><p>The effect of IKK&#x003b2; gene silencing on IKK&#x003b2; protein expression was determined in primary cultured human myotubes. Two days after induction of the myotube differentiation program, cells were transfected with siRNA against IKK&#x003b2;. Expression of IKK&#x003b2; was unaltered in cells exposed to a scrambled siRNA sequence or following 2 h of incubation with TNF-&#x003b1; (<xref rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>). siRNA against IKK&#x003b2; reduced protein expression 73&#x00025;, (<xref rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>) (<italic>P</italic> &#x0003c; 0.05) and mRNA expression by 55&#x00025; (<italic>P</italic> &#x0003c; 0.01) (data not shown) compared with cells transfected with scrambled siRNA. Following TNF-&#x003b1; exposure (2 h, 20 ng/ml), protein content of I&#x003ba;&#x003b2;&#x003b1; was reduced (<xref rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>), indicating that I&#x003ba;&#x003b2;&#x003b1; was targeted for degradation after cytokine exposure. siRNA against IKK&#x003b2; increased the basal expression of I&#x003ba;&#x003b2;&#x003b1; and blunted the TNF-&#x003b1;&#x02013;mediated reduction. Myotube growth and morphology was unaltered after IKK&#x003b2; silencing (<xref rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>). Expression of the myogenic protein desmin following 6 days of differentiation (4 days after transfection) was unaltered between myotubes treated with siRNA against a scrambled sequence or IKK&#x003b2; (<xref rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>).</p></sec><sec><title>Effect of IKK&#x003b2; silencing on glucose uptake and metabolism.</title><p>We have reported that an acute TNF-&#x003b1; exposure impairs insulin-stimulated glucose uptake and glycogen synthesis in cultured human skeletal muscle (<xref ref-type="bibr" rid="r22">22</xref>). Here, we determined whether TNF-&#x003b1;&#x02013;induced insulin resistance is prevented by IKK&#x003b2; silencing. Four days after transfection, glucose uptake (<xref rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>) and incorporation into glycogen (<xref rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>) was assessed under basal and insulin-stimulated conditions in the presence or absence of TNF-&#x003b1;. In control cells or cells transfected with scrambled siRNA, insulin (120 nmol/l) increased glucose uptake 1.7-fold (<italic>P</italic> &#x0003c; 0.05) and glycogen synthesis 3.8-fold (<italic>P</italic> &#x0003c; 0.05). Basal glucose transport and incorporation to glycogen was unaltered in cells exposed to TNF-&#x003b1;. However, TNF-&#x003b1; pretreatment reduced insulin action on glucose uptake (<italic>P</italic> &#x0003c; 0.05) and incorporation to glycogen (<italic>P</italic> &#x0003c; 0.05). Silencing of IKK&#x003b2; had no effect on either basal or insulin-stimulated glucose metabolism. Importantly, siRNA-mediated silencing of IKK&#x003b2; prevented the inhibitory effect of TNF-&#x003b1; on insulin-mediated glucose metabolism.</p></sec><sec><title>Effect of IKK&#x003b2; silencing on Akt phosphorylation.</title><p>Insulin increased Akt Ser<sup>473</sup> and Thr<sup>308</sup> phosphorylation in primary cultures of human skeletal muscle (<xref rid="f4" ref-type="fig">Fig. 4<italic>A</italic> and <italic>B</italic></xref>, respectively). Insulin action on Akt was unaltered in cells transfected with scrambled siRNA. TNF-&#x003b1; impaired insulin action on Akt Ser<sup>473</sup> and Thr<sup>308</sup> phosphorylation (<italic>P</italic> &#x0003c; 0.05). IKK&#x003b2; silencing had no effect on basal (data not shown) or insulin-stimulated Akt Ser<sup>473</sup> or Thr<sup>308</sup> phosphorylation but prevented the TNF-&#x003b1;&#x02013;induced impairment. Protein expression of Akt was unaltered in response to insulin, TNF-&#x003b1;, or gene silencing (<xref rid="f4" ref-type="fig">Fig. 4<italic>C</italic></xref>).</p></sec><sec><title>Effect of IKK&#x003b2; silencing on GSK3&#x003b2; and AS160 phosphorylation.</title><p>To further evaluate the effect of IKK&#x003b2; on insulin signaling, phosphorylation of the Akt substrates GSK3&#x003b2; and AS160 was determined. Insulin increased phosphorylation of GSK3&#x003b2; Ser<sup>9</sup> (<xref rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>) and AS160 (<xref rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>) in primary cultures of human skeletal muscle. These responses were unaltered in cells transfected with scrambled siRNA. TNF-&#x003b1; treatment increased GSK3&#x003b2; Ser<sup>9</sup> phosphorylation to the same extent as insulin but had no effect on insulin-mediated phosphorylation. Silencing of IKK&#x003b2; had no effect on basal or insulin-stimulated GSK3&#x003b2; Ser<sup>9</sup> and prevented the TNF-&#x003b1;&#x02013;induced increase in GSK3&#x003b2; phosphorylation. TNF-&#x003b1; treatment prevented the insulin-mediated increase in AS160 phosphorylation, and silencing of IKK&#x003b2; restored this insulin effect.</p></sec><sec><title>Effect of IKK&#x003b2; silencing on ERK 1/2 MAPK phosphorylation.</title><p>Insulin increased ERK 1/2 MAPK phosphorylation (<italic>P</italic> &#x0003c; 0.05) in primary cultures of human skeletal muscle (<xref rid="f6" ref-type="fig">Fig. 6<italic>A</italic></xref>&#x02013;<italic>C</italic>). Insulin action on ERK 1/2 MAPK was unaltered in cells transfected with scrambled siRNA. TNF-&#x003b1; exposure increased basal ERK 1/2 MAPK phosphorylation (<italic>P</italic> &#x0003c; 0.05), although to a lesser extent than observed in response to insulin. TNF-&#x003b1; exposure did not modify insulin action on ERK 1/2 MAPK phosphorylation. IKK&#x003b2; silencing had no effect on ERK 1/2 MAPK phosphorylation either in the absence or presence of insulin and/or TNF-&#x003b1;. Total ERK expression was unaltered in response to TNF-&#x003b1; exposure or siRNA gene silencing. To further explore the role of ERK in the mediation of TNF-&#x003b1;&#x02013;induced impairments in insulin-mediated glucose metabolism, we determined the effect of the MEK inhibitor PD98059 on glycogen synthesis in response to insulin and TNF-&#x003b1; (<xref rid="f6" ref-type="fig">Fig. 6<italic>D</italic></xref>). Exposure of primary cultures to PD98059 reduced insulin and TNF-&#x003b1;&#x02013;mediated ERK1/2 phosphorylation (data not shown). However, this inhibitor had no effect on glycogen synthesis in response to insulin or TNF-&#x003b1; exposure.</p></sec><sec><title>Effect of IKK&#x003b2; silencing on JNK phosphorylation.</title><p>Insulin increased p54 and p46 JNK phosphorylation (<italic>P</italic> &#x0003c; 0.05) in primary cultures of human skeletal muscle (<xref rid="f7" ref-type="fig">Fig. 7</xref>). Insulin action on p54 and p46 JNK was unaltered in cells transfected with scrambled siRNA. Similar to results noted for ERK1/2 MAPK, TNF-&#x003b1; exposure increased basal p54 and p46 JNK phosphorylation, and IKK&#x003b2; silencing had no effect on JNK phosphorylation either in the absence or presence of insulin and/or TNF-&#x003b1;.</p></sec><sec><title>Effect of IKK&#x003b2; silencing on IRS-1 gel mobility or Ser<sup>312</sup> phosphorylation.</title><p>TNF-&#x003b1; exposure is associated with increased phosphorylation of IRS-1 on Ser<sup>312</sup>. Thus, we determined whether IKK&#x003b2; plays a role in TNF-&#x003b1;&#x02013;mediated IRS-1 Ser<sup>312</sup> phosphorylation in primary human myotubes. Insulin and TNF-&#x003b1; increased IRS-1 Ser<sup>312</sup> phosphorylation (<xref rid="f8" ref-type="fig">Fig. 8<italic>A</italic></xref>), and this response was unaltered in cells transfected with siRNA against either a scrambled sequence or IKK&#x003b2;. To evaluate the total phosphorylation status of IRS-1, a gel mobility shift assay was performed. Insulin and TNF-&#x003b1; induced an upward mobility shift in IRS-1 migration in SDS-PAGE (<xref rid="f8" ref-type="fig">Fig. 8<italic>B</italic></xref>), indicating increased phosphorylation. The effect of insulin on IRS-1 mobility was unaltered in cells transfected with scrambled siRNA. IKK&#x003b2; silencing had no effect on the mobility shift of IRS-1 in response to either insulin or TNF-&#x003b1; exposure. Thus, IKK&#x003b2; does not appear to mediate TNF-&#x003b1;&#x02013;induced phosphorylation events on IRS-1.</p></sec><sec><title>Effect of IKK&#x003b2; silencing on mRNA and protein expression.</title><p>Gene silencing of IKK&#x003b2; did not alter either GLUT1 or GLUT4 mRNA (105 &#x000b1; 31 or 87 &#x000b1; 12&#x00025;, respectively, as compared with cells transfected with a scrambled sequence). Because we have recently reported that MAP4K4 siRNA prevents TNF-&#x003b1;&#x02013;induced insulin resistance (<xref ref-type="bibr" rid="r22">22</xref>), protein expression of MAP4K4 and the upstream kinase MAP2K4 was also assessed in cells transfected with siRNA against a scrambled sequence or IKK&#x003b2;. Protein content of either MAP4K4 or MAP2K4 was unaltered in myotubes transfected with scrambled or IKK&#x003b2; siRNA (data not shown).</p></sec></sec><sec><title>DISCUSSION</title><p>IKK&#x003b2; is a core component of the oligomeric IKK complex, which consists of two catalytic subunits, IKK&#x003b1; and IKK&#x003b2;, and a regulatory subunit IKK&#x003b3;, or NEMO (<xref ref-type="bibr" rid="r16">16</xref>,<xref ref-type="bibr" rid="r18">18</xref>,<xref ref-type="bibr" rid="r30">30</xref>,<xref ref-type="bibr" rid="r31">31</xref>). The two catalytic subunits share &#x0223c;50&#x00025; amino acid sequence homology, whereas the regulatory subunit does not contain a recognizable catalytic domain (<xref ref-type="bibr" rid="r21">21</xref>). Despite the overall sequence identity between IKK&#x003b1; and IKK&#x003b2;, these subunits have specialized roles as mediators of cellular stress. For example, deletion of IKK&#x003b1; (<italic>IKK&#x003b1;</italic><sup>&#x02212;</sup><sup>/</sup><sup>&#x02212;</sup>) causes limb deformities (<xref ref-type="bibr" rid="r31">31</xref>), whereas deletion of IKK&#x003b2; (<italic>IKK&#x003b2;</italic><sup>&#x02212;/&#x02212;</sup>) is lethal in mouse embryos (<xref ref-type="bibr" rid="r32">32</xref>). Of the two catalytic subunits, IKK&#x003b2; is considered to be the main regulator of NF-&#x003ba;B function because of its higher activity (&#x0223c;30-fold) toward I&#x003ba;B&#x003b1; (<xref ref-type="bibr" rid="r17">17</xref>,<xref ref-type="bibr" rid="r33">33</xref>). Recent evidence underscores a central role of IKK&#x003b2; in insulin sensitivity and type 2 diabetes pathogenesis (<xref ref-type="bibr" rid="r2">2</xref>,<xref ref-type="bibr" rid="r3">3</xref>,<xref ref-type="bibr" rid="r20">20</xref>,<xref ref-type="bibr" rid="r21">21</xref>,<xref ref-type="bibr" rid="r34">34</xref>,<xref ref-type="bibr" rid="r35">35</xref>). High doses of salicylates, which repress IKK&#x003b2; activity, reverse hyperglycemia, hyperinsulinemia, and dyslipidemia in obese rodents by increasing insulin sensitivity (<xref ref-type="bibr" rid="r2">2</xref>,<xref ref-type="bibr" rid="r3">3</xref>,<xref ref-type="bibr" rid="r20">20</xref>,<xref ref-type="bibr" rid="r21">21</xref>). Consequently, we determined the role of IKK&#x003b2; in insulin action on glucose uptake using siRNA-mediated gene silencing. We provide evidence that IKK&#x003b2; plays a role in TNF-&#x003b1;&#x02013;induced impairments in insulin action on Akt signaling and glucose uptake and metabolism in human skeletal muscle.</p><p>TNF-&#x003b1; has a biphasic response to NF-&#x003ba;B, which is required for cytokine-induced skeletal muscle damage and wasting/cachexia (<xref ref-type="bibr" rid="r36">36</xref>,<xref ref-type="bibr" rid="r37">37</xref>). Cytokines activate the IKK complex, leading to phosphorylation of I&#x003ba;B&#x003b1; on Ser<sup>32</sup> and Ser<sup>36</sup>. Phosphorylation of these residues causes polyubiquitination and subsequent degradation of I&#x003ba;B&#x003b1; by proteosomes (<xref ref-type="bibr" rid="r16">16</xref>). The breakdown of I&#x003ba;B&#x003b1; leads to the release and nuclear translocation of NF-&#x003ba;B, where it binds to target genes and drives the expression of cytokines, including TNF-&#x003b1;, interleukin-6, and interleukin-1&#x003b2; (<xref ref-type="bibr" rid="r38">38</xref>). Here, we report that a 2-h TNF-&#x003b1; exposure of cultured myotubes decreased I&#x003ba;&#x003b2;&#x003b1; protein content, indicating that I&#x003ba;&#x003b2;&#x003b1; is targeted for degradation after cytokine exposure. This finding is consistent with the first transient phase of TNF-&#x003b1;&#x02013;mediated activation of NF-&#x003ba;B (<xref ref-type="bibr" rid="r37">37</xref>). The siRNA-mediated reduction of IKK&#x003b2; prevented the TNF-&#x003b1; effect on I&#x003ba;&#x003b2;&#x003b1; degradation. Skeletal muscle wasting/cachexia, due to accelerated protein degradation through ubiquitin-dependent proteolysis, occurs in a manner analogous to IKK&#x003b2;-mediated degradation of I&#x003ba;B&#x003b1;. Genetic inhibition of the IKK&#x003b2;/NF-&#x003ba;B/MuRF1 pathway or through pharmacological therapeutics, such as salicylates to inhibit IKK&#x003b2; activity, rescues the skeletal muscle-wasting phenotype (<xref ref-type="bibr" rid="r37">37</xref>,<xref ref-type="bibr" rid="r39">39</xref>,<xref ref-type="bibr" rid="r40">40</xref>). In the current study, skeletal muscle morphology was not altered by either TNF-&#x003b1; exposure or siRNA-mediated gene silencing of IKK&#x003b2;. However, our experiments were limited to a short-term (first phase) TNF-&#x003b1; exposure, and we did not directly test whether IKK&#x003b2; siRNA would modify culture growth in the presence of a long-term (second phase) TNF-&#x003b1; exposure.</p><p>TNF-&#x003b1; directly induces skeletal muscle insulin resistance in vivo in healthy humans (<xref ref-type="bibr" rid="r1">1</xref>) and rodents (<xref ref-type="bibr" rid="r41">41</xref>,<xref ref-type="bibr" rid="r42">42</xref>) and in vitro in cultured myotubes (<xref ref-type="bibr" rid="r22">22</xref>). Although the role of TNF-&#x003b1; in the development of skeletal muscle insulin resistance in type 2 diabetic patients remains unresolved, current evidence suggests that IKK&#x003b2; may be an intermediate kinase through which TNF-&#x003b1; and other inflammatory processes induce skeletal muscle insulin resistance (<xref ref-type="bibr" rid="r5">5</xref>,<xref ref-type="bibr" rid="r6">6</xref>,<xref ref-type="bibr" rid="r35">35</xref>). IKK&#x003b2; activation has been closely linked to the development and pathogenesis of insulin resistance (<xref ref-type="bibr" rid="r20">20</xref>,<xref ref-type="bibr" rid="r21">21</xref>). Pharmacological inhibition of IKK&#x003b2; activity improves insulin-mediated glucose metabolism (<xref ref-type="bibr" rid="r3">3</xref>,<xref ref-type="bibr" rid="r20">20</xref>,<xref ref-type="bibr" rid="r21">21</xref>), even in insulin-resistant obese, nondiabetic individuals (<xref ref-type="bibr" rid="r43">43</xref>). Increased expression of IKK&#x003b2; has been noted in omental fat from obese humans, potentially contributing to differential roles of omental and subcutaneous fat in the pathophysiology of obesity (<xref ref-type="bibr" rid="r44">44</xref>).</p><p>Studies linking IKK&#x003b2; and skeletal muscle insulin resistance in rodents have yielded conflicting results. Pharmacological IKK&#x003b2; inhibition ameliorated insulin resistance and upregulated plasma levels of adiponectin in KKAy mice fed a high-fat diet (<xref ref-type="bibr" rid="r45">45</xref>). Heterozygous IKK&#x003b2;<sup>&#x0002b;/&#x02212;</sup> mice fed a high-fat diet or intergressed on an obese <italic>ob/ob</italic> mice background were protected against the development of insulin resistance (<xref ref-type="bibr" rid="r3">3</xref>). Conversely, mice with either skeletal muscle&#x02013;specific IKK&#x003b2; knockout or a separate cohort of heterozygous IKK&#x003b2;<sup>&#x0002b;/&#x02212;</sup> were not protected against gold thioglucose&#x02013;induced obesity or dietary-induced metabolic abnormalities (<xref ref-type="bibr" rid="r46">46</xref>). The reason for the differences noted between these animal models is unknown, but the differences could be strain specific or related to undefined experimental differences.</p><p>TNF-&#x003b1; exposure leads to activation of two separate transcription factor&#x02013;signaling pathways, namely the IKK&#x003b2; and JNK pathways, which are linked to proinflammatory responses associated with obesity and insulin resistance (<xref ref-type="bibr" rid="r47">47</xref>). Here, we show that siRNA-mediated gene silencing of IKK&#x003b2; prevented TNF-&#x003b1;&#x02013;induced insulin resistance on glucose uptake and metabolism in cultured myotubes, with a concomitant increase in phosphorylation of Akt (at Ser<sup>473</sup>, Thr<sup>308</sup>), and AS160. Inhibition of ERK signaling using pharmacological inhibitor PD98059 did not alter TNF-&#x003b1;&#x02013;mediated reduction in insulin-stimulated glycogen synthesis. Furthermore, the TNF-&#x003b1;&#x02013;mediated activation of ERK and JNK was unaffected by the siRNA-mediated reduction of IKK&#x003b2;. Additionally, the siRNA-mediated reduction of IKK&#x003b2; did not prevent TNF-&#x003b1;&#x02013;induced IRS-1 serine phosphorylation on Ser<sup>312</sup> or the IRS-1 mobility shift as determined by SDS-PAGE. This is in contrast to some reports indicating that inhibition of IKK&#x003b2; prevents IRS-1 Ser<sup>307</sup> (equivalent to human IRS-1 Ser<sup>312</sup>) phosphorylation in cultured HEPG2, 3T3-L1 adipocytes, or embryonic kidney cells (<xref ref-type="bibr" rid="r25">25</xref>,<xref ref-type="bibr" rid="r26">26</xref>,<xref ref-type="bibr" rid="r48">48</xref>) but is consistent with other observations that IKK&#x003b2; is disassociated from IRS-1 phosphorylation (Steven E. Shoelson, Joslin Diabetes Center, Boston, MA, personal communication). Our results indicate that the TNF-&#x003b1; effect on IRS-1 serine phosphorylation is primarily mediated via parallel IKK&#x003b2; independent pathways, such as JNK.</p><p>IKK&#x003b2; silencing fully restored the TNF-&#x003b1;&#x02013;mediated reduction of insulin-stimulated glucose metabolism, despite modest impairments in insulin signaling at the level of Akt. However, TNF-&#x003b1; exposure was associated with a profound impairment in insulin-stimulated AS160 phosphorylation, which was restored following IKK&#x003b2; silencing. Since AS160 is a critical step in the processes involved from insulin signaling to glucose transport, this may explain the enhanced glucose metabolism in IKK&#x003b2;-depleted myotubes. Our results may also indicate that a relatively small pool of total Akt is critical for signaling to AS160, and this pool may be highly sensitive to TNF-&#x003b1;, possibly due to cellular localization.</p><p>In primary cultures of human muscle, TNF-&#x003b1; exposure enhanced phosphorylation of GSK3&#x003b2;. This finding is consistent with a finding of a previous study in HEK293 cells and mouse embryonic fibroblasts (<xref ref-type="bibr" rid="r49">49</xref>), where TNF-&#x003b1;&#x02013;mediated activation of ERK was partly dependent on GSK3&#x003b2; phosphorylation. Conversely, TNF-&#x003b1; exposure has also been shown to prevent insulin-stimulated phosphorylation of GSK3&#x003b2; in HEPG2 cells (<xref ref-type="bibr" rid="r50">50</xref>). Here, we report that IKK&#x003b2; silencing prevents the TNF-&#x003b1;&#x02013;mediated increase in GSK3&#x003b2; phosphorylation; however, the functional consequence requires further investigation. Although GSK3&#x003b2; Ser<sup>9</sup> phosphorylation has been linked to a reduction in the constitutive ability of GSK3 to phosphorylate Ser<sup>641</sup> of glycogen synthase, it does not completely abolish the ability of GSK3 to phosphorylate glycogen synthase (<xref ref-type="bibr" rid="r51">51</xref>). Thus, further studies are warranted to establish whether GSK3 activity is modulated.</p><p>MAP4K4 is a member of the NCK interacting kinase family (<xref ref-type="bibr" rid="r23">23</xref>). NCK interacting kinase family kinases are potent activators of the IKK complex and activators of ERK and JNK (<xref ref-type="bibr" rid="r34">34</xref>), which suggests that MAP4K4 is likely to be an upstream regulator of IKK&#x003b2;. Here, we show that siRNA-mediated silencing of IKK&#x003b2; had no effect on expression of MAP4K4, excluding a negative feedback on this upstream kinase. We have previously reported that the siRNA-mediated reduction of MAP4K4 rescues TNF-&#x003b1;&#x02013;mediated insulin resistance in primary human skeletal muscle cultures (<xref ref-type="bibr" rid="r22">22</xref>), consistent with our present findings for IKK&#x003b2;. Although a reduction of either MAP4K4 or IKK&#x003b2; prevents the effect of TNF-&#x003b1; on insulin-mediated glucose uptake and metabolism, the reduction of MAP4K4 also prevented IRS-1 serine phosphorylation and signaling to ERK 1/2 and JNK. In contrast, siRNA silencing of IKK&#x003b2; did not alter TNF-&#x003b1; signaling to either IRS-1 Ser<sup>312</sup>, JNK, or ERK phosphorylation. These results are consistent with the hypothesis that downstream signals from MAP4K4 diverge toward an ERK/JNK pathway that mediates effects on IRS-1 serine phosphorylation and an IKK&#x003b2; pathway that mediates effects on glucose uptake and metabolism.</p><p>In summary, targeted deletion of IKK&#x003b2; using siRNA prevents TNF-&#x003b1;&#x02013;mediated insulin resistance on Akt and AS160 phosphorylation and glucose uptake and metabolism in human skeletal muscle. These results underscore IKK&#x003b2; as a potential therapeutic target to prevent peripheral insulin resistance.</p></sec></body><back><ack><p>This study was supported by grants from the Swedish Research Council, the Swedish Medical Association, the Novo-Nordisk Foundation, the Swedish Diabetes Association, the Swedish Animal Welfare Agency, the Hedlund Foundation, the Strategic Research Foundation, and the Commission of the European Communities (contract no. LSHM-CT-2004-005272 EXGENESIS, contract no. LSHM-CT-2004-512013 EUGENEHEART, and contract no. LSHM-CT-2004-512013 EUGENE2).</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><citation citation-type="journal">Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK: Tumor necrosis factor-&#x003b1; induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. <source>Diabetes</source><volume>54</volume>: <fpage>2939</fpage>&#x02013;2945, <year>2005</year><pub-id pub-id-type="pmid">16186396</pub-id></citation></ref><ref id="r2"><label>2</label><citation citation-type="journal">Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. <source>Nature</source><volume>396</volume>: <fpage>77</fpage>&#x02013;80, <year>1998</year><pub-id pub-id-type="pmid">9817203</pub-id></citation></ref><ref id="r3"><label>3</label><citation citation-type="journal">Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. <source>Science</source><volume>293</volume>: <fpage>1673</fpage>&#x02013;1677, <year>2001</year><pub-id pub-id-type="pmid">11533494</pub-id></citation></ref><ref id="r4"><label>4</label><citation citation-type="journal">Ruotsalainen E, Salmenniemi U, Vauhkonen I, Pihlajamaki J, Punnonen K, Kainulainen S, Laakso M: Changes in inflammatory cytokines are related to impaired glucose tolerance in offspring of type 2 diabetic subjects. <source>Diabetes Care</source><volume>29</volume>: <fpage>2714</fpage>&#x02013;2720, <year>2006</year><pub-id pub-id-type="pmid">17130210</pub-id></citation></ref><ref id="r5"><label>5</label><citation citation-type="journal">Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. <source>J Clin Invest</source><volume>116</volume>: <fpage>1793</fpage>&#x02013;1801, <year>2006</year><pub-id pub-id-type="pmid">16823477</pub-id></citation></ref><ref id="r6"><label>6</label><citation citation-type="journal">Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AFH: Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. <source>Diabetes</source><volume>52</volume>: <fpage>812</fpage>&#x02013;817, <year>2003</year><pub-id pub-id-type="pmid">12606524</pub-id></citation></ref><ref id="r7"><label>7</label><citation citation-type="journal">Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. <source>J Clin Invest</source><volume>95</volume>: <fpage>2409</fpage>&#x02013;2415, <year>1995</year><pub-id pub-id-type="pmid">7738205</pub-id></citation></ref><ref id="r8"><label>8</label><citation citation-type="journal">Feingold KR, Grunfeld C: Role of cytokines in inducing hyperlipidemia. <source>Diabetes</source><volume>41</volume> (Suppl. 2): <fpage>S97</fpage>&#x02013;S101, <year>1992</year></citation></ref><ref id="r9"><label>9</label><citation citation-type="journal">Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M: Relationship between serum tumor necrosis factor-alpha and insulin resistance in obese men with Type 2 diabetes mellitus. <source>Diabetes Res Clin Pract</source><volume>52</volume>: <fpage>119</fpage>&#x02013;123, <year>2001</year><pub-id pub-id-type="pmid">11311966</pub-id></citation></ref><ref id="r10"><label>10</label><citation citation-type="journal">Winkler G, Lakatos P, Nagy Z, Speer G, Salamon F, Szekeres O, Kovacs M, Cseh K: Elevated serum tumor necrosis factor-alpha and endothelin 1 levels correlate with increased C-peptide concentration in android type obesity. <source>Diabetes Care</source><volume>21</volume>: <fpage>1778</fpage>&#x02013;1779, <year>1998</year><pub-id pub-id-type="pmid">9773752</pub-id></citation></ref><ref id="r11"><label>11</label><citation citation-type="journal">Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA: The expression of TNF alpha by human muscle: relationship to insulin resistance. <source>J Clin Invest</source><volume>97</volume>: <fpage>1111</fpage>&#x02013;1116, <year>1996</year><pub-id pub-id-type="pmid">8613535</pub-id></citation></ref><ref id="r12"><label>12</label><citation citation-type="journal">Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G: Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. <source>Diabetes</source><volume>52</volume>: <fpage>1799</fpage>&#x02013;1805, <year>2003</year><pub-id pub-id-type="pmid">12829649</pub-id></citation></ref><ref id="r13"><label>13</label><citation citation-type="journal">Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. <source>Lancet</source><volume>353</volume>: <fpage>1649</fpage>&#x02013;1652, <year>1999</year><pub-id pub-id-type="pmid">10335783</pub-id></citation></ref><ref id="r14"><label>14</label><citation citation-type="journal">Zhou Z, Connell MC, Macewan DJ: TNFR1-induced NF-kappaB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cells. <source>Cell Signal</source><volume>19</volume>: <fpage>1238</fpage>&#x02013;1248, <year>2007</year><pub-id pub-id-type="pmid">17292586</pub-id></citation></ref><ref id="r15"><label>15</label><citation citation-type="journal">Karin M: The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. <source>J Biol Chem</source><volume>274</volume>: <fpage>27339</fpage>&#x02013;27342, <year>1999</year><pub-id pub-id-type="pmid">10488062</pub-id></citation></ref><ref id="r16"><label>16</label><citation citation-type="journal">Karin M, Delhase M: The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. <source>Semin Immunol</source><volume>12</volume>: <fpage>85</fpage>&#x02013;98, <year>2000</year><pub-id pub-id-type="pmid">10723801</pub-id></citation></ref><ref id="r17"><label>17</label><citation citation-type="journal">Huynh QK, Boddupalli H, Rouw SA, Koboldt CM, Hall T, Sommers C, Hauser SD, Pierce JL, Combs RG, Reitz BA, Diaz-Collier JA, Weinberg RA, Hood BL, Kilpatrick BF, Tripp CS: Characterization of the recombinant IKK1/IKK2 heterodimer: mechanisms regulating kinase activity. <source>J Biol Chem</source><volume>275</volume>: <fpage>25883</fpage>&#x02013;25891, <year>2000</year><pub-id pub-id-type="pmid">10823818</pub-id></citation></ref><ref id="r18"><label>18</label><citation citation-type="journal">Verma UN, Yamamoto Y, Prajapati S, Gaynor RB: Nuclear role of I kappa B Kinase-gamma/NF-kappa B essential modulator (IKK gamma/NEMO) in NF-kappa B-dependent gene expression. <source>J Biol Chem</source><volume>279</volume>: <fpage>3509</fpage>&#x02013;3515, <year>2004</year><pub-id pub-id-type="pmid">14597638</pub-id></citation></ref><ref id="r19"><label>19</label><citation citation-type="journal">Shoelson SE, Lee J, Yuan M: Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. <source>Int J Obes Relat Metab Disord</source><volume>27</volume>: <fpage>S49</fpage>&#x02013;S52, <year>2003</year><pub-id pub-id-type="pmid">14704745</pub-id></citation></ref><ref id="r20"><label>20</label><citation citation-type="journal">Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI: Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. <source>J Clin Invest</source><volume>109</volume>: <fpage>1321</fpage>&#x02013;1326, <year>2002</year><pub-id pub-id-type="pmid">12021247</pub-id></citation></ref><ref id="r21"><label>21</label><citation citation-type="journal">Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI: Prevention of fat-induced insulin resistance by salicylate. <source>J Clin Invest</source><volume>108</volume>: <fpage>437</fpage>&#x02013;446, <year>2001</year><pub-id pub-id-type="pmid">11489937</pub-id></citation></ref><ref id="r22"><label>22</label><citation citation-type="journal">Bouzakri K, Zierath JR: MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. <source>J Biol Chem</source><volume>282</volume>: <fpage>7783</fpage>&#x02013;7789, <year>2007</year><pub-id pub-id-type="pmid">17227768</pub-id></citation></ref><ref id="r23"><label>23</label><citation citation-type="journal">Tang X, Guilherme A, Chakladar A, Powelka AM, Konda S, Virbasius JV, Nicoloro SM, Straubhaar J, Czech MP: An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARgamma, adipogenesis, and insulin-responsive hexose transport. <source>Proc Natl Acad Sci U S A</source><volume>103</volume>: <fpage>2087</fpage>&#x02013;2092, <year>2006</year><pub-id pub-id-type="pmid">16461467</pub-id></citation></ref><ref id="r24"><label>24</label><citation citation-type="journal">Machida N, Umikawa M, Takei K, Sakima N, Myagmar BE, Taira K, Uezato H, Ogawa Y, Kariya K: Mitogen-activated protein kinase kinase kinase kinase 4 as a putative effector of Rap2 to activate the c-Jun N-terminal kinase. <source>J Biol Chem</source><volume>279</volume>: <fpage>15711</fpage>&#x02013;15714, <year>2004</year><pub-id pub-id-type="pmid">14966141</pub-id></citation></ref><ref id="r25"><label>25</label><citation citation-type="journal">Gao Z, Zuberi A, Quon MJ, Dong Z, Ye J: Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. <source>J Biol Chem</source><volume>278</volume>: <fpage>24944</fpage>&#x02013;24950, <year>2003</year><pub-id pub-id-type="pmid">12714600</pub-id></citation></ref><ref id="r26"><label>26</label><citation citation-type="journal">Jiang G, Dallas-Yang Q, Liu F, Moller DE, Zhang BB: Salicylic acid reverses phorbol 12-myristate-13-acetate (PMA)- and tumor necrosis factor alpha (TNFalpha)-induced insulin receptor substrate 1 (IRS1) serine 307 phosphorylation and insulin resistance in human embryonic kidney 293 (HEK293) cells. <source>J Biol Chem</source><volume>278</volume>: <fpage>180</fpage>&#x02013;186, <year>2003</year><pub-id pub-id-type="pmid">12409308</pub-id></citation></ref><ref id="r27"><label>27</label><citation citation-type="journal">Al-Khalili L, Chibalin AV, Kannisto K, Zhang BB, Permert J, Holman GD, E E, Ding VDH, Zierath JR, Krook A: Insulin action in cultured human skeletal muscle cells during differentiation: assessment of cell surface GLUT4 and GLUT1 content. <source>Cell Mol Life Sci</source><volume>60</volume>: <fpage>991</fpage>&#x02013;998, <year>2003</year><pub-id pub-id-type="pmid">12827286</pub-id></citation></ref><ref id="r28"><label>28</label><citation citation-type="journal">Bouzakri K, Zachrisson A, Al-Khalili L, Zhang BB, Koistinen HA, Krook A, Zierath JR: siRNA-based gene silencing reveals specialized roles of IRS-1/Akt2 and IRS-2/Akt1 in glucose and lipid metabolism in human skeletal muscle. <source>Cell Metab</source><volume>4</volume>: <fpage>89</fpage>&#x02013;96, <year>2006</year><pub-id pub-id-type="pmid">16814735</pub-id></citation></ref><ref id="r29"><label>29</label><citation citation-type="journal">Al-Khalili L, Bouzakri K, Glund S, L&#x000f6;nnqvist F, Koistinen HA, Krook A: Signalling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. <source>Mol Endocrinol</source><volume>20</volume>: <fpage>3364</fpage>&#x02013;3375, <year>2006</year><pub-id pub-id-type="pmid">16945991</pub-id></citation></ref><ref id="r30"><label>30</label><citation citation-type="journal">Brasier AR: The NF-kappaB regulatory network. <source>Cardiovasc Toxicol</source><volume>6</volume>: <fpage>111</fpage>&#x02013;130, <year>2006</year><pub-id pub-id-type="pmid">17303919</pub-id></citation></ref><ref id="r31"><label>31</label><citation citation-type="journal">Hu Y, Baud V, Delhase M, Zhang P, Deerinck T, Ellisman M, Johnson R, Karin M: Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. <source>Science</source><volume>284</volume>: <fpage>316</fpage>&#x02013;320, <year>1999</year><pub-id pub-id-type="pmid">10195896</pub-id></citation></ref><ref id="r32"><label>32</label><citation citation-type="journal">Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM: Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. <source>Science</source><volume>284</volume>: <fpage>321</fpage>&#x02013;325, <year>1999</year><pub-id pub-id-type="pmid">10195897</pub-id></citation></ref><ref id="r33"><label>33</label><citation citation-type="journal">Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV: IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. <source>Science</source><volume>278</volume>: <fpage>866</fpage>&#x02013;869, <year>1997</year><pub-id pub-id-type="pmid">9346485</pub-id></citation></ref><ref id="r34"><label>34</label><citation citation-type="journal">Hu WH, Pendergast JS, Mo XM, Brambilla R, Bracchi-Ricard V, Li F, Walters WM, Blits B, He L, Schaal SM, Bethea JR: NIBP, a novel NIK and IKK(beta)-binding protein that enhances NF-(kappa)B activation. <source>J Biol Chem</source><volume>280</volume>: <fpage>29233</fpage>&#x02013;29241, <year>2005</year><pub-id pub-id-type="pmid">15951441</pub-id></citation></ref><ref id="r35"><label>35</label><citation citation-type="journal">Sriwijitkamol A, Christ-Roberts C, Berria R, Eagan P, Pratipanawatr T, DeFronzo RA, Mandarino LJ, Musi N: Reduced skeletal muscle inhibitor of &#x003ba;B&#x003b2; content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training. <source>Diabetes</source><volume>55</volume>: <fpage>760</fpage>&#x02013;767, <year>2006</year><pub-id pub-id-type="pmid">16505240</pub-id></citation></ref><ref id="r36"><label>36</label><citation citation-type="journal">Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE: Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. <source>Nat Med</source><volume>11</volume>: <fpage>183</fpage>&#x02013;190, <year>2005</year><pub-id pub-id-type="pmid">15685173</pub-id></citation></ref><ref id="r37"><label>37</label><citation citation-type="journal">Ladner KJ, Caligiuri MA, Guttridge DC: Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. <source>J Biol Chem</source><volume>278</volume>: <fpage>2294</fpage>&#x02013;2303, <year>2003</year><pub-id pub-id-type="pmid">12431991</pub-id></citation></ref><ref id="r38"><label>38</label><citation citation-type="journal">Tak PP, Firestein GS: NF-kappaB: a key role in inflammatory diseases. <source>J Clin Invest</source><volume>107</volume>: <fpage>7</fpage>&#x02013;11, <year>2001</year><pub-id pub-id-type="pmid">11134171</pub-id></citation></ref><ref id="r39"><label>39</label><citation citation-type="journal">Kramer HF, Goodyear LJ: Exercise, MAPK, and NF-kappaB signaling in skeletal muscle. <source>J Appl Physiol</source><volume>103</volume>: <fpage>388</fpage>&#x02013;395, <year>2007</year><pub-id pub-id-type="pmid">17303713</pub-id></citation></ref><ref id="r40"><label>40</label><citation citation-type="journal">Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE: IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. <source>Cell</source><volume>119</volume>: <fpage>285</fpage>&#x02013;298, <year>2004</year><pub-id pub-id-type="pmid">15479644</pub-id></citation></ref><ref id="r41"><label>41</label><citation citation-type="journal">Cheung AT, Ree D, Kolls JK, Fuselier J, Coy DH, Bryer-Ash M: An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-alpha. <source>Endocrinology</source><volume>139</volume>: <fpage>4928</fpage>&#x02013;4935, <year>1998</year><pub-id pub-id-type="pmid">9832430</pub-id></citation></ref><ref id="r42"><label>42</label><citation citation-type="journal">Steinberg GR, Michell BJ, van Denderen BJ, Watt MJ, Carey AL, Fam BC, Andrikopoulos S, Proietto J, Gorgun CZ, Carling D, Hotamisligil GS, Febbraio MA, Kay TW, Kemp BE: Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. <source>Cell Metab</source><volume>4</volume>: <fpage>465</fpage>&#x02013;474, <year>2006</year><pub-id pub-id-type="pmid">17141630</pub-id></citation></ref><ref id="r43"><label>43</label><citation citation-type="journal">Fleischman A, Shoelson SE, Bernier R, Goldfine AB: Salsalate improves glycemia and inflammatory parameters in obese young adults. <source>Diabetes Care</source><volume>31</volume>: <fpage>289</fpage>&#x02013;294, <year>2008</year><pub-id pub-id-type="pmid">17959861</pub-id></citation></ref><ref id="r44"><label>44</label><citation citation-type="journal">Bashan N, Dorfman K, Tarnovscki T, Harman-Boehm I, Liberty IF, Bluher M, Ovadia S, Maymon-Zilberstein T, Potashnik R, Stumvoll M, Avinoach E, Rudich A: Mitogen-activated protein kinases, inhibitory-kappaB Kinase, and insulin signaling in human omental versus subcutaneous adipose tissue in obesity. <source>Endocrinology</source><volume>148</volume>: <fpage>2955</fpage>&#x02013;2962, <year>2007</year><pub-id pub-id-type="pmid">17317777</pub-id></citation></ref><ref id="r45"><label>45</label><citation citation-type="journal">Kamon J, Yamauchi T, Muto S, Takekawa S, Ito Y, Hada Y, Ogawa W, Itai A, Kasuga M, Tobe K, Kadowaki T: A novel IKKbeta inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance. <source>Biochem Biophys Res Comm</source><volume>323</volume>: <fpage>242</fpage>&#x02013;248, <year>2004</year><pub-id pub-id-type="pmid">15351728</pub-id></citation></ref><ref id="r46"><label>46</label><citation citation-type="journal">Rohl M, Pasparakis M, Baudler S, Baumgartl J, Gautam D, Huth M, De Lorenzi R, Krone W, Rajewsky K, Bruning JC: Conditional disruption of IkappaB kinase 2 fails to prevent obesity-induced insulin resistance. <source>J Clin Invest</source><volume>113</volume>: <fpage>474</fpage>&#x02013;481, <year>2004</year><pub-id pub-id-type="pmid">14755344</pub-id></citation></ref><ref id="r47"><label>47</label><citation citation-type="journal">Shoelson SE, Herrero L, Naaz A: Obesity, inflammation, and insulin resistance. <source>Gastroenterology</source><volume>132</volume>: <fpage>2169</fpage>&#x02013;2180, <year>2007</year><pub-id pub-id-type="pmid">17498510</pub-id></citation></ref><ref id="r48"><label>48</label><citation citation-type="journal">de Alvaro C, Teruel T, Hernandez R, Lorenzo M: Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. <source>J Biol Chem</source><volume>279</volume>: <fpage>17070</fpage>&#x02013;17078, <year>2004</year><pub-id pub-id-type="pmid">14764603</pub-id></citation></ref><ref id="r49"><label>49</label><citation citation-type="journal">Kim JW, Lee JE, Kim MJ, Cho EG, Cho SG, Choi EJ: Glycogen synthase kinase 3beta is a natural activator of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1). <source>J Biol Chem</source><volume>278</volume>: <fpage>13995</fpage>&#x02013;14001, <year>2003</year><pub-id pub-id-type="pmid">12584189</pub-id></citation></ref><ref id="r50"><label>50</label><citation citation-type="journal">Gupta D, Varma S, Khandelwal RL: Long-term effects of tumor necrosis factor-alpha treatment on insulin signaling pathway in HepG2 cells and HepG2 cells overexpressing constitutively active Akt/PKB. <source>J Cell Biochem</source><volume>100</volume>: <fpage>593</fpage>&#x02013;607, <year>2007</year><pub-id pub-id-type="pmid">16960890</pub-id></citation></ref><ref id="r51"><label>51</label><citation citation-type="journal">Martin M, Rehani K, Jope RS, Michalek SM: Toll-like receptor&#x02013;mediated cytokine production is differentially regulated by glycogen synthase kinase 3. <source>Nat Immunol</source><volume>6</volume>: <fpage>777</fpage>&#x02013;784, <year>2005</year><pub-id pub-id-type="pmid">16007092</pub-id></citation></ref></ref-list></back><floats-wrap><fig position="float" id="f1"><label>FIG. 1.</label><caption><p>Protein expression of IKK&#x003b2; and I&#x003ba;B&#x003b1;. <italic>A</italic>: Protein expression of IKK&#x003b2; was unaltered in cells exposed to a scrambled siRNA sequence, a 2-h incubation with TNF-&#x003b1; (<italic>lanes</italic><italic>1&#x02013;3</italic>). siRNA against IKK&#x003b2; reduced protein expression by 73&#x00025; (<italic>lanes</italic><italic>4 and 5</italic>). Glyceraldehyde-3-phosphate dehydrogenase (GADPH) expression was determined to control for equal loading. <italic>B</italic>: I&#x003ba;B&#x003b1; was measured after siRNA-mediated depletion of IKK&#x003b2;. Results are means &#x000b1; SE. &#x0002a;<italic>P</italic> &#x0003c; 0.05 vs. transfected scrambled siRNA (Scr) control (<italic>n</italic> &#x0003d; 4).</p></caption><graphic xlink:href="zdb0080853890001"></graphic></fig><fig position="float" id="f2"><label>FIG. 2.</label><caption><p>Myotube growth. <italic>A</italic>: Morphological appearance of human skeletal muscle myotube formation after introduction of scrambled siRNA or siRNA against IKK&#x003b2;. Photomicrographs are shown at 10&#x000d7; magnification for myotubes at day 6 of differentiation (4 days after introduction of siRNA). Results are from two separate experiments. <italic>B</italic>: Representative immunoblot showing the differentiation marker desmin.</p></caption><graphic xlink:href="zdb0080853890002"></graphic></fig><fig position="float" id="f3"><label>FIG. 3.</label><caption><p>Effect of siRNA-mediated silencing of IKK&#x003b2; on glucose uptake and glycogen synthesis. Glucose uptake (<italic>A</italic>) and glycogen synthesis (<italic>B</italic>) were measured in differentiated primary skeletal muscle myotubes under basal conditions (&#x025a1;) and after insulin stimulation (&#x025aa;). Results are means &#x000b1; SE. &#x0002a;<italic>P</italic> &#x0003c; 0.05 vs. respective basal cells. &#x02020;<italic>P</italic> &#x0003c; 0.05 vs. TNF-&#x003b1;&#x02013;and insulin-stimulated untransfected cells (<italic>n</italic> &#x0003d; 4).</p></caption><graphic xlink:href="zdb0080853890003"></graphic></fig><fig position="float" id="f4"><label>FIG. 4.</label><caption><p>Akt Ser<sup>473</sup> and Thr<sup>308</sup> phosphorylation. Representative immunoblot showing Akt Ser<sup>473</sup> (<italic>A</italic>) and Akt Thr<sup>308</sup> (<italic>B</italic>) phosphorylation in response to insulin and TNF-&#x003b1;. <italic>C</italic>: Total Akt protein expression. Graphs are summarized data (mean &#x000b1; SE). &#x0002a;<italic>P</italic> &#x0003c; 0.05&#x00025; vs. untransfected control cells. &#x02020;<italic>P</italic> &#x0003c; 0.05 vs. TNF-&#x003b1;&#x02013;stimulated untransfected cells (<italic>n</italic> &#x0003d; 9).</p></caption><graphic xlink:href="zdb0080853890004"></graphic></fig><fig position="float" id="f5"><label>FIG. 5.</label><caption><p>GSK-3&#x003b2; and AS160 phosphorylation. Representative immunoblot showing pGSK3&#x003b2; Ser<sup>9</sup> (<italic>A</italic>) and Akt substrate AS160 (<italic>B</italic>) phosphorylation in response to insulin or TNF-&#x003b1; under basal conditions (&#x025a1;) and after insulin stimulation (&#x025aa;). Graphs are summarized data (mean &#x000b1; SE). &#x0002a;<italic>P</italic> &#x0003c; 0.05 vs. respective basal. &#x02020;<italic>P</italic> &#x0003c; 0.05 vs. TNF-&#x003b1;&#x02013;stimulated untransfected cells. #<italic>P</italic> &#x0003c; 0.05 vs. control basal (GSK3&#x003b2;, <italic>n</italic> &#x0003d; 3; AS160, <italic>n</italic> &#x0003d; 4).</p></caption><graphic xlink:href="zdb0080853890005"></graphic></fig><fig position="float" id="f6"><label>FIG. 6.</label><caption><p>Effect of siRNA-mediated silencing of IKK&#x003b2; on ERK1/2 MAPK phosphorylation. <italic>A</italic>: Representative immunoblot of ERK1/2 MAPK phosphorylation. <italic>B</italic>: Total ERK-2 protein expression. <italic>C</italic>: Summarized results for ERK1/2 MAPK under basal (&#x025a1;) or insulin-stimulated (&#x025aa;) conditions. (<italic>n</italic> &#x0003d; 5). <italic>D</italic>: Glycogen synthesis was measured in differentiated primary skeletal muscle myotubes following 1 h of exposure to 50 &#x003bc;mol/l PD98059. Results are means &#x000b1; SE from experiment carried out in triplicate. &#x0002a;<italic>P</italic> &#x0003c; 0.05 vs. respective basal. #<italic>P</italic> &#x0003c; 0.05 vs. control basal.</p></caption><graphic xlink:href="zdb0080853890006"></graphic></fig><fig position="float" id="f7"><label>FIG. 7.</label><caption><p>Effect of siRNA-mediated silencing of IKK&#x003b2; on JNK phosphorylation. <italic>A</italic>: Representative immunoblot showing p54/p46 JNK phosphorylation. <italic>B</italic>: Summarized results for p54 and p46 JNK phosphorylation under basal (&#x025a1;) or insulin-stimulated (&#x025aa;) conditions. Results are mean &#x000b1; SE. &#x0002a;<italic>P</italic> &#x0003c; 0.05 vs. respective basal. #<italic>P</italic> &#x0003c; 0.05 vs. control basal (<italic>n</italic> &#x0003d; 3).</p></caption><graphic xlink:href="zdb0080853890007"></graphic></fig><fig position="float" id="f8"><label>FIG. 8.</label><caption><p>Effect of siRNA-mediated silencing of IKK&#x003b2; on IRS-1 Ser<sup>312</sup> phosphorylation. Representative immunoblot showing IRS-1 migration on SDS-PAGE (<italic>A</italic>) or IRS-1 Ser<sup>312</sup> phosphorylation (<italic>B</italic>). IRS-1 Ser<sup>312</sup> phosphorylation results under basal (&#x025a1;) and insulin-stimulated (&#x025aa;) conditions are reported as means &#x000b1; SE percent relative to basal untransfected controls. Arrow highlights mobility shift (<italic>A</italic>) (<italic>n</italic> &#x0003d; 4).</p></caption><graphic xlink:href="zdb0080853890008"></graphic></fig></floats-wrap></article> 